过敏诊断市场 - 全球产业规模、份额、趋势、机会及预测（按产品、过敏原类型、检测方法、最终用户、地区和竞争格局划分），2021-2031年

全球过敏诊断市场预计将从 2025 年的 65.8 亿美元成长到 2031 年的 129.8 亿美元，复合年增长率达到 11.99%。

此领域利用医疗设备、耗材和检测方法来识别过敏原特异性抗体和细胞反应，从而实现对环境和食物来源过敏原的临床诊断。市场成长的主要驱动力是全球特应性疾病发生率的上升以及临床上对早期检测以有效管理慢性疾病的需求。根据美国气喘和过敏基金会 (AAFA) 2024 年的一份报告，美国约有 1 亿人患有各种过敏性疾病，这凸显了建立可靠的诊断框架以应对这一日益严重的健康问题的迫切需求。

然而，自动化诊断平台的高昂实施和营运成本为市场带来了许多障碍。这些资金限制常常阻碍小规模实验室和资源有限的医疗机构部署全面的检测方案。因此，在医疗预算紧张的发展中经济体，高成本抑制了市场渗透，有效限制了这些重要诊断工具的广泛应用。

市场驱动因素

全球过敏性疾病及其併发症的盛行率不断上升，加上快速的都市化和环境污染加剧，成为过敏诊断市场成长的主要驱动力。气候变迁导致空气品质恶化和花粉季延长，增加了呼吸道过敏的发生率，从而催生了对更频繁、更精准的筛检通讯协定的需求。根据美国气喘和过敏基金会 (AAFA) 2024 年 3 月发布的《2024 年首都地区过敏状况》报告，约 25.7% 的美国成年人被诊断出患有季节性过敏。这种普遍存在的疾病负担迫使医疗保健提供者使用综合诊断方案来区分过敏性鼻炎与其他呼吸道疾病，从而推动了免疫检测设备和耗材试剂盒在临床环境中的应用。

同时，严重食物过敏和食物超敏反应发生率的快速成长是推动市场发展的主要因素，因此，精准的风险评估工具至关重要。食物超敏反应的复杂性促使临床关注转向成分解析诊断，以识别引发过敏反应的特定蛋白质。世界过敏组织2024年3月发表的一篇报导指出，FARE患者登记库中46%的患者曾发生食物诱发的过敏反应，凸显了进行更高级风险分层的必要性。此外，英国食品标准局（FSA）2024年8月的报告显示，英格兰因食物诱发的过敏反应而入院治疗的人数已增至每10万人4.02人，这更加凸显了临床上迫切需要可靠的诊断干预措施。

市场挑战

自动化诊断平台高昂的采集费用和营运成本严重阻碍因素了过敏诊断市场的扩张。中小实验室往往缺乏足够的资金来购买此类设备以及承担耗材和维护的持续成本。这项经济障碍使得资源充足的医疗中心难以获得全面的检测服务，导致小规模的机构和资源匮乏的地区无法获得充分的服务。因此，在医疗支出受到严格控制和优先考虑的发展中经济体，市场渗透更是难上加难。

根据欧洲过敏与临床免疫学会的估计，到2024年，欧洲约有1.5亿人将患有慢性过敏性疾病。儘管患病率高且诊断需求巨大，但小规模医疗机构无力实施自动化系统，导致临床需求与检测能力之间存在差距。大多数医疗机构诊断基础设施的资金不足限制了患者就医，直接限制了检测量，并阻碍了整体市场成长。

市场趋势

将人工智慧 (AI) 和机器学习 (ML) 整合到诊断工作流程中，透过自动化解读复杂的免疫学数据，从根本上改变了过敏检测的方式。这些先进的演算法分析患者的病历和致敏模式，以比传统人工评估更高的准确率预测过敏原反应，从而显着减轻临床医生的行政负担。正如 2024 年 10 月发表于《欧洲公共卫生杂誌》的论文「AI 增强型过敏诊断」中所详述的，一项约 300 名患者的临床试验证实，AI 辅助方法在保持高灵敏度的同时，平均每位医务人员可节省 40 分钟的检测时间。这项技术变革透过简化高风险患者的分层流程和优化临床决策，有效缓解了专科医师短缺的问题。

同时，市场正经历着向多重免疫检测和微阵列平台的重大转变，这些平台能够从单一血清样本中同时定量检测针对多种过敏原的特异性IgE抗体。这一发展趋势推动了成分解析诊断（CRD）的广泛应用，使医疗专业人员能够比单次检测法更有效地区分真正的致敏反应和交叉反应。在该领域，AliveDx于2024年7月发布新闻稿，宣布其专有的微阵列免疫免疫检测已获得监管部门核准，该技术可检测30多种不同的过敏原，包括食物和吸入性蛋白质。此类平台对于制定针对多重过敏患者的个人化管理方案而言正变得越来越重要，且无需采集大量血液样本。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球过敏诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（检测试剂盒、仪器、耗材、服务）
  • 过敏类型（食物、季节性、药物、吸入性、过敏性/接触性、其他）
  • 依测试方法（体内测试、体外测试）
  • 依最终使用者（医院、诊断检查室、学术研究机构等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美过敏诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲过敏诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区过敏诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲过敏诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲过敏诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球过敏诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• Abbott Laboratories
• Danaher Corporation
• Hologic, Inc.
• BioMerieux SA
• F. Hoffmann-La Roche AG
• Laboratory Corporation of America Holdings
• Allergy Therapeutics plc
• Indoor Biotechnologies, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Allergy Diagnostics Market is projected to expand from USD 6.58 Billion in 2025 to USD 12.98 Billion by 2031, achieving a CAGR of 11.99%. This sector involves the medical instruments, consumables, and assays used to identify allergen-specific antibodies or cellular responses, enabling the clinical diagnosis of hypersensitivities to environmental and food-based triggers. Market growth is primarily fueled by the rising global incidence of atopic diseases and the clinical necessity for early detection to manage chronic conditions effectively. As reported by the Asthma and Allergy Foundation of America in 2024, approximately 100 million individuals in the United States live with various allergic conditions, underscoring the critical need for reliable diagnostic frameworks to address this expanding health burden.

However, the market encounters significant hurdles due to the high acquisition and operational costs associated with automated diagnostic platforms. These financial constraints frequently limit the adoption of comprehensive testing panels in smaller laboratories and resource-limited healthcare settings. Consequently, high costs impede market penetration in developing economic regions where healthcare budgets are tight, effectively restricting the widespread availability of these essential diagnostic tools.

Market Driver

The rising global prevalence of allergic diseases and comorbidities, exacerbated by rapid urbanization and environmental pollution, serves as a primary catalyst for the growth of the allergy diagnostics market. As climate change degrades air quality and prolongs pollen seasons, the frequency of respiratory sensitizations has increased, creating a demand for more frequent and precise screening protocols. According to the March 2024 '2024 Allergy Capitals' report by the Asthma and Allergy Foundation of America, approximately 25.7% of adults in the United States have a diagnosed seasonal allergy. This widespread burden compels healthcare providers to utilize comprehensive diagnostic panels to distinguish allergic rhinitis from other respiratory conditions, thereby boosting the deployment of immunoassay analyzers and consumable kits in clinical settings.

Simultaneously, the market is significantly propelled by the surging incidence of severe food allergies and dietary sensitivities, which necessitate accurate risk assessment tools. The complexity of food-based hypersensitivities has shifted clinical focus toward component-resolved diagnostics to pinpoint specific proteins that trigger anaphylaxis. In the 'The clinical burden of food allergies' article published by the World Allergy Organization in March 2024, 46% of patients in the FARE Patient Registry reported experiencing food-induced anaphylaxis, highlighting the need for advanced stratification. Furthermore, the Food Standards Agency's August 2024 report noted that hospital admissions for food-induced anaphylaxis in England rose to 4.02 per 100,000 people, reinforcing the urgent clinical imperative for robust diagnostic interventions.

Market Challenge

The substantial acquisition and operational expenses tied to automated diagnostic platforms pose a major restraint on the expansion of the allergy diagnostics market. Small and medium-sized laboratories often lack the capital budget necessary to purchase these instruments or support the recurring costs of consumables and maintenance. This financial barrier effectively restricts the use of comprehensive testing panels to well-funded medical centers, leaving smaller facilities and resource-constrained regions underserved. Consequently, the market struggles to penetrate developing economic regions where healthcare spending is strictly monitored and prioritized.

According to the European Academy of Allergy and Clinical Immunology, approximately 150 million citizens across Europe were estimated to suffer from chronic allergic diseases in 2024. Despite this high prevalence and the associated need for diagnosis, the inability of smaller healthcare providers to afford automated systems creates a disparity between clinical demand and testing availability. When diagnostic infrastructure is financially inaccessible to a large segment of the healthcare landscape, patient access is reduced, which directly limits the volume of assays performed and impedes overall market growth.

Market Trends

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into diagnostic workflows is fundamentally transforming allergy testing by automating the interpretation of complex immunological data. These advanced algorithms analyze patient history and sensitization patterns to predict allergen reactivity with greater precision than traditional manual assessments, significantly lowering administrative burdens on clinicians. As detailed in the 'AI-Enhanced Allergy Diagnostics' article within the European Journal of Public Health in October 2024, clinical trials involving around 300 patients showed that AI-supported methods saved medical staff an average of 40 minutes per patient while maintaining high sensitivity. This technological shift addresses specialist shortages by streamlining the stratification of high-risk patients and optimizing clinical decision-making.

Concurrently, the market is witnessing a decisive shift toward Multiplex Immunoassay and Microarray Platforms, which allow for the simultaneous quantification of specific IgE antibodies against a vast array of allergens from a single serum sample. This evolution supports the broader adoption of Component-Resolved Diagnostics (CRD), enabling practitioners to differentiate between genuine sensitization and cross-reactivity more effectively than single-plex assays. A significant advancement in this area was highlighted by AliveDx in a July 2024 press release, announcing regulatory approval for its proprietary microarray immunoassay designed to detect over 30 distinct allergens, including both food and inhalant proteins. Such platforms are increasingly critical for developing personalized management plans for polysensitized individuals without requiring large blood volumes.

Key Market Players

• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• Abbott Laboratories
• Danaher Corporation
• Hologic, Inc.
• BioMerieux SA
• F. Hoffmann-La Roche AG
• Laboratory Corporation of America Holdings
• Allergy Therapeutics plc
• Indoor Biotechnologies, Inc.

Report Scope

In this report, the Global Allergy Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Diagnostics Market, By Product

• Assay Kits
• Instruments
• Consumables
• Services

Allergy Diagnostics Market, By Allergy Type

• Food
• Seasonal
• Drug
• Inhalant
• Anaphylaxis/Contact Allergies
• Others

Allergy Diagnostics Market, By Test

• In Vivo
• In Vitro

Allergy Diagnostics Market, By End User

• Hospital
• Diagnostic Laboratory
• Academic and Research Institutes
• Others

Allergy Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Diagnostics Market.

Available Customizations:

Global Allergy Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Assay Kits, Instruments, Consumables, Services)
  • 5.2.2. By Allergy Type (Food, Seasonal, Drug, Inhalant, Anaphylaxis/Contact Allergies, Others)
  • 5.2.3. By Test (In Vivo, In Vitro)
  • 5.2.4. By End User (Hospital, Diagnostic Laboratory, Academic and Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Allergy Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Allergy Type
  • 6.2.3. By Test
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Allergy Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Allergy Type
      • 6.3.1.2.3. By Test
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Allergy Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Allergy Type
      • 6.3.2.2.3. By Test
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Allergy Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Allergy Type
      • 6.3.3.2.3. By Test
      • 6.3.3.2.4. By End User

7. Europe Allergy Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Allergy Type
  • 7.2.3. By Test
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Allergy Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Allergy Type
      • 7.3.1.2.3. By Test
      • 7.3.1.2.4. By End User
  • 7.3.2. France Allergy Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Allergy Type
      • 7.3.2.2.3. By Test
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Allergy Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Allergy Type
      • 7.3.3.2.3. By Test
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Allergy Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Allergy Type
      • 7.3.4.2.3. By Test
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Allergy Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Allergy Type
      • 7.3.5.2.3. By Test
      • 7.3.5.2.4. By End User

8. Asia Pacific Allergy Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Allergy Type
  • 8.2.3. By Test
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Allergy Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Allergy Type
      • 8.3.1.2.3. By Test
      • 8.3.1.2.4. By End User
  • 8.3.2. India Allergy Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Allergy Type
      • 8.3.2.2.3. By Test
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Allergy Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Allergy Type
      • 8.3.3.2.3. By Test
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Allergy Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Allergy Type
      • 8.3.4.2.3. By Test
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Allergy Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Allergy Type
      • 8.3.5.2.3. By Test
      • 8.3.5.2.4. By End User

9. Middle East & Africa Allergy Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Allergy Type
  • 9.2.3. By Test
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Allergy Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Allergy Type
      • 9.3.1.2.3. By Test
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Allergy Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Allergy Type
      • 9.3.2.2.3. By Test
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Allergy Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Allergy Type
      • 9.3.3.2.3. By Test
      • 9.3.3.2.4. By End User

10. South America Allergy Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Allergy Type
  • 10.2.3. By Test
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Allergy Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Allergy Type
      • 10.3.1.2.3. By Test
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Allergy Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Allergy Type
      • 10.3.2.2.3. By Test
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Allergy Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Allergy Type
      • 10.3.3.2.3. By Test
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Allergy Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Siemens Healthineers AG
• 15.3. Abbott Laboratories
• 15.4. Danaher Corporation
• 15.5. Hologic, Inc.
• 15.6. BioMerieux SA
• 15.7. F. Hoffmann-La Roche AG
• 15.8. Laboratory Corporation of America Holdings
• 15.9. Allergy Therapeutics plc
• 15.10. Indoor Biotechnologies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer